If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Omvoh ® (mirikizumab-mrkz) injection
300 mg/15 mL, 100 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is Omvoh® (mirikizumab-mrkz) for Crohn's disease citrate-free?
A citrate-free formulation of mirikizumab-mrkz for the treatment of Crohn's disease has been approved.
Citrate-Free Mirikizumab for Crohn's Disease
The US Food and Drug Administration has approved a citrate-free formulation of mirikizumab-mrkz for the treatment of Crohn's disease. The citrate-free formulation for Crohn's disease will be available as a prefilled syringe and a prefilled pen for subcutaneous administration and is expected to be available in the first half of 2025.1-3
Enclosed Prescribing Information
References
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease. Press release. Eli Lilly and Company; January 15, 2025. Accessed January 30, 2025. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-omvohr-mirikizumab-mrkz-crohns-disease
3Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: January 30, 2025